The complexity of NF-κB signaling in inflammation and cancer

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Hoesel, Bastian ^a   Schmid, Johannes A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer; Cooperativity; Crosstalk; Inflammation; NF kappa B signaling

Indexed keywords

ANTIANDROGEN; I KAPPA B ALPHA; I KAPPA B BETA; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE EPSILON; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; PROTEASOME INHIBITOR; PROTEIN BCL 3; PROTEIN P100; PROTEIN P105; PROTEIN P50; PROTEIN P52; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

ACETYLATION; ANDROGEN SYNTHESIS; ANTIANDROGEN THERAPY; APOPTOSIS; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; ENZYME PHOSPHORYLATION; GENE MUTATION; HODGKIN DISEASE; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROMOTER REGION; PROTEIN INTERACTION; PROTEIN METHYLATION; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; T CELL LYMPHOMA; UBIQUITINATION;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MICRORNAS; NEOPLASMS; NF-KAPPA B; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84880869807     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-86     Document Type: Review

References (168)

1. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986, 46:705-716. 10.1016/0092-8674(86)90346-6, 3091258.
2. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998, 19:80-88. 10.1016/S0167-5699(97)01197-3, 9509763.
3. Caamaño J, Hunter CA. NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev 2002, 15:414-429. 10.1128/CMR.15.3.414-429.2002, 118079, 12097249.
4. May MJ, Ghosh S. Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer Biol 1997, 8:63-73. 10.1006/scbi.1997.0057, 9299584.
5. Marienfeld R. RelB forms transcriptionally inactive complexes with RelA/p65. J Biol Chem 2003, 278:19852-19860. 10.1074/jbc.M301945200, 12657634.
6. Hayden MSM, Ghosh SS. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012, 26:203-234. 10.1101/gad.183434.111, 3278889, 22302935.
7. Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 1993, 72:729-739. 10.1016/0092-8674(93)90401-B, 8453667.
8. Franzoso G, Bours V, Azarenko V, Park S, Tomita-Yamaguchi M, Kanno T, Brown K, Siebenlist U. The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. EMBO J 1993, 12:3893-3901. 413672, 8404857.
9. Nolan GP, Fujita T, Bhatia K, Huppi C, Liou HC, Scott ML, Baltimore D. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol 1993, 13:3557-3566. 359825, 8497270.
10. Wong D, Teixeira A, Oikonomopoulos S, Humburg P, Lone IN, Saliba D, Siggers T, Bulyk M, Angelov D, Dimitrov S, Udalova IA, Ragoussis J. Extensive characterization of NF-κB binding uncovers non-canonical motifs and advances the interpretation of genetic functional traits. Genome Biol 2011, 12:R70. 10.1186/gb-2011-12-7-r70, 3218832, 21801342.
11. Oeckinghaus A, Ghosh S. The NF- B family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009, 1:a000034-a000034. 10.1101/cshperspect.a000034, 2773619, 20066092.
12. Birbach A, Gold P, Binder BR, Hofer E, De Martin R, Schmid JA. Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J Biol Chem 2002, 277:10842-10851. 10.1074/jbc.M112475200, 11801607.
13. Huang TT, Kudo N, Yoshida M, Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci USA 2000, 97:1014-1019. 10.1073/pnas.97.3.1014, 15505, 10655476.
14. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362. 10.1016/j.cell.2008.01.020, 18267068.
15. Tan P, Fuchs SY, Chen A, Wu K, Gomez C, Ronai Z, Pan ZQ. Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of I kappa B alpha. Mol Cell 1999, 3:527-533. 10.1016/S1097-2765(00)80481-5, 10230406.
16. Wu K, Fuchs SY, Chen A, Tan P, Gomez C, Ronai Z, Pan ZQ. The SCF(HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol Cell Biol 2000, 20:1382-1393. 10.1128/MCB.20.4.1382-1393.2000, 85290, 10648623.
17. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science 1999, 284:309-313. 10.1126/science.284.5412.309, 10195894.
18. Schmid JA, Birbach A. IkappaB kinase beta (IKKbeta/IKK2/IKBKB)-a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev 2008, 19:157-165. 10.1016/j.cytogfr.2008.01.006, 18308615.
19. Ling L, Cao Z, Goeddel DV. NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci USA 1998, 95:3792-3797. 10.1073/pnas.95.7.3792, 19916, 9520446.
20. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997, 385:540-544. 10.1038/385540a0, 9020361.
21. Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, Okumura K. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA 1998, 95:3537-3542. 10.1073/pnas.95.7.3537, 19871, 9520401.
22. Zhao Q. Mitogen-activated protein Kinase/ERK Kinase Kinases 2 and 3 activate nuclear factor-kappa B through Ikappa B Kinase-alpha and Ikappa B Kinase-beta. J Biol Chem 1999, 274:8355-8358. 10.1074/jbc.274.13.8355, 10085062.
23. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999, 398:252-256. 10.1038/18465, 10094049.
24. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001, 412:346-351. 10.1038/35085597, 11460167.
25. Huang Q, Yang J, Lin Y, Walker C, Cheng J, Liu Z-G, Su B. Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nat Immunol 2003, 5:98-103.
26. Qin J. TLR8-mediated NF- B and JNK Activation Are TAK1-independent and MEKK3-dependent. J Biol Chem 2006, 281:21013-21021. 10.1074/jbc.M512908200, 16737960.
27. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000, 103:351-361. 10.1016/S0092-8674(00)00126-4, 11057907.
28. Habelhah H, Takahashi S, Cho S-G, Kadoya T, Watanabe T, Ronai Z. Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J 2004, 23:322-332. 10.1038/sj.emboj.7600044, 1271753, 14713952.
29. Iwai K, Tokunaga F. Linear polyubiquitination: a new regulator of NF-κB activation. EMBO Rep 2009, 10:706-713. 10.1038/embor.2009.144, 2727427, 19543231.
30. Tokunaga F, Sakata S-I, Saeki Y, Satomi Y, Kirisako T, Kamei K, Nakagawa T, Kato M, Murata S, Yamaoka S, Yamamoto M, Akira S, Takao T, Tanaka K, Iwai K. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nat Cell Biol 2009, 11:123-132. 10.1038/ncb1821, 19136968.
31. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004, 430:694-699. 10.1038/nature02794, 15258597.
32. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003, 424:793-796. 10.1038/nature01803, 12917689.
33. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 2006, 13:759-772. 10.1038/sj.cdd.4401838, 16410803.
34. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007, 8:49-62. 10.1038/nrm2083, 17183360.
35. Sun S-C. Non-canonical NF-κB signaling pathway. Cell Res 2010, 21:71-85. 3193406, 21173796.
36. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 2001, 7:401-409. 10.1016/S1097-2765(01)00187-3, 11239468.
37. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li Z-W, Karin M, Ware CF, Green DR. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002, 17:525-535. 10.1016/S1074-7613(02)00423-5, 12387745.
38. Solan NJ, Miyoshi H, Carmona EM, Bren GD, Paya CV. RelB cellular regulation and transcriptional activity are regulated by p100. J Biol Chem 2002, 277:1405-1418. 10.1074/jbc.M109619200, 11687592.
39. Senftleben U, Cao Y, Xiao G, Greten FR, Krähn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293:1495-1499. 10.1126/science.1062677, 11520989.
40. Huang TT, Wuerzberger-Davis SM, Wu Z-H, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 2003, 115:565-576. 10.1016/S0092-8674(03)00895-X, 14651848.
41. Kato T, Delhase M, Hoffmann A, Karin M. CK2 Is a C-terminal IkappaB Kinase responsible for NF-kappaB activation during the UV response. Mol Cell 2003, 12:829-839. 10.1016/S1097-2765(03)00358-7, 14580335.
42. Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S, Aggarwal BB. Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem 2003, 278:24233-24241. 10.1074/jbc.M212389200, 12711606.
43. Habib AA. The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome. J Biol Chem 2000, 276:8865-8874.
44. Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, Sensi M, Canevari S, Tomassetti A. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 2011, 31:4139-4149.
45. Tieri P, Termanini A, Bellavista E, Salvioli S, Capri M, Franceschi C. Charting the NF-κB pathway interactome map. PLoS ONE 2012, 7:e32678. 10.1371/journal.pone.0032678, 3293857, 22403694.
46. Latimer M, Ernst MK, Dunn LL, Drutskaya M, Rice NR. The N-terminal domain of IkappaB alpha masks the nuclear localization signal(s) of p50 and c-Rel homodimers. Mol Cell Biol 1998, 18:2640-2649. 110643, 9566883.
47. Bouwmeester T, Bauch A, Ruffner H, Angrand P-O, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon A-M, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari G, Drewes G, Gavin A-C, Jackson DB, Joberty G, Neubauer G, Rick J, Kuster B, Superti-Furga G. A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nat Cell Biol 2004, 6:97-105. 10.1038/ncb1086, 14743216.
48. Scheinman RI, Beg AA, Baldwin AS. NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule. Mol Cell Biol 1993, 13:6089-6101. 364669, 8413211.
49. Barré B, Perkins ND. A cell cycle regulatory network controlling NF-κB subunit activity and function. EMBO J 2007, 26:4841-4855. 10.1038/sj.emboj.7601899, 2099464, 17962807.
50. Ashburner BP, Westerheide SD, Baldwin AS. The p65 (RelA) subunit of NF- B interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001, 21:7065-7077. 10.1128/MCB.21.20.7065-7077.2001, 99882, 11564889.
51. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 1997, 94:2927-2932. 10.1073/pnas.94.7.2927, 20299, 9096323.
52. Chapman NR, Webster GA, Gillespie PJ, Wilson BJ, Crouch DH, Perkins ND. A novel form of the RelA nuclear factor kappaB subunit is induced by and forms a complex with the proto-oncogene c-Myc. Biochem J 2002, 366:459-469. 10.1042/BJ20020444, 1222795, 12027803.
53. Frank AK, Leu JI-J, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, Hollstein M, Murphy ME. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 2011, 31:1201-1213. 10.1128/MCB.01136-10, 3067895, 21245379.
54. Anrather J, Racchumi G, Iadecola C. cis-acting, element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B. Journal of Biological Chemistry 2004, 280:244-252.
55. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003, 22:1313-1324. 10.1093/emboj/cdg139, 151081, 12628924.
56. Nihira K, Ando Y, Yamaguchi T, Kagami Y, Miki Y, Yoshida K. Pim-1 controls NF. Cell Death and Differentiation 2009, 17:689-698.
57. Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S. The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997, 89:413-424. 10.1016/S0092-8674(00)80222-6, 9150141.
58. Jamaluddin M, Wang S, Boldogh I, Tian B, Brasier AR. TNF-α-induced NF-κB/RelA Ser276 phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal 2007, 19:1419-1433. 10.1016/j.cellsig.2007.01.020, 17317104.
59. Duran A, Diaz-Meco MT, Moscat J. Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J 2003, 22:3910-3918. 10.1093/emboj/cdg370, 169043, 12881425.
60. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 2002, 283:G204-G211.
61. Yang F, Tang E, Guan K, Wang C-Y. IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 2003, 170:5630-5635.
62. Schwabe RF. IKK phosphorylates p65 at S468 in transactivaton domain 2 2005, The: FASEB Journal.
63. Buss H. Constitutive and interleukin-1-inducible phosphorylation of p65 NF- B at serine 536 is mediated by multiple protein kinases including I B kinase (IKK)-, IKK, IKK, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. Journal of Biological Chemistry 2004, 279:55633-55643. 10.1074/jbc.M409825200, 15489227.
64. Mattioli I, Geng H, Sebald A, Hodel M, Bucher C, Kracht M, Schmitz ML. Inducible Phosphorylation of NF- B p65 at Serine 468 by T Cell Costimulation Is Mediated by IKK. Journal of Biological Chemistry 2006, 281:6175-6183. 10.1074/jbc.M508045200, 16407239.
65. Wang D. Tumor necrosis factor alpha -induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. Journal of Biological Chemistry 2000, 275:32592-32597.
66. Soon Bae J, Kyoo Jang M, Hong S, An WG, Choi YH, Kim HD, Cheong J. Phosphorylation of NF-κB by calmodulin-dependent kinase IV activates anti-apoptotic gene expression. Biochem Biophys Res Commun 2003, 305:1094-1098. 10.1016/S0006-291X(03)00869-6, 12767944.
67. Delhase M, Kim SY, Lee H, Naiki-Ito A, Chen Y, Ahn ER, Murata K, Kim SJ, Lautsch N, Kobayashi KS, Shirai T, Karin M, Nakanishi M. PNAS Plus: TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2. Proceedings of the National Academy of Sciences 2012, 109:E177-E186.
68. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005, 434:1138-1143. 10.1038/nature03491, 15858576.
69. Bohuslav J. p53 Induces NF- B activation by an I B kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. Journal of Biological Chemistry 2004, 279:26115-26125. 10.1074/jbc.M313509200, 15073170.
70. Sabatel H, Di Valentin E, Gloire G, Dequiedt F, Piette J, Habraken Y. Phosphorylation of p65(RelA) on Ser547 by ATM represses NF-κB-dependent transcription of specific genes after genotoxic stress. PLoS ONE 2012, 7:e38246. 10.1371/journal.pone.0038246, 3371017, 22715377.
71. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou Y-C, Wulf G, Rottapel R, Yamaoka S, Lu KP. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Molecular Cell 2003, 12:1413-1426. 10.1016/S1097-2765(03)00490-8, 14690596.
72. Yeh PY. Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF- B activation by protein phosphatase 4-mediated NF- B p65 Thr dephosphorylation. Journal of Biological Chemistry 2004, 279:26143-26148. 10.1074/jbc.M402362200, 15073167.
73. Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND. Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J 2005, 24:1157-1169. 10.1038/sj.emboj.7600608, 556410, 15775976.
74. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866. 10.1038/sj.onc.1203239, 10602461.
75. Klement JF, Rice NR, Car BD, Abbondanzo SJ, Powers GD, Bhatt PH, Chen CH, Rosen CA, Stewart CL. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol Cell Biol 1996, 16:2341-2349. 231222, 8628301.
76. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 2011, 12:715-723.
77. Disis ML. Immune regulation of cancer. J Clin Oncol 2010, 28:4531-4538. 10.1200/JCO.2009.27.2146, 3041789, 20516428.
78. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006, 90:1-50.
79. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360. 10.1146/annurev.immunol.22.012703.104803, 15032581.
80. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999, 19:5785-5799. 84428, 10409765.
81. La Rosa FA, Pierce JW, Sonenshein GE. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol 1994, 14:1039-1044. 358459, 8289784.
82. Perkins ND. Achieving transcriptional specificity with NF-kappa B. The international journal of biochemistry & cell biology 1997, 29:1433-1448. 10.1016/S1357-2725(97)00088-5, 20833257.
83. Liou G-Y, Storz P. Reactive oxygen species in cancer. Free Radic Res 2010, 44:479-496. 10.3109/10715761003667554, 20370557.
84. Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Investig 2004, 114:569-581. 503772, 15314694.
85. Xie T-X, Xia Z, Zhang N, Gong W, Huang S. Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol Rep 2010, 23:725-732.
86. Yoshida A, Yoshida S, Ishibashi T, Kuwano M, Inomata H. Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice. Invest Ophthalmol Vis Sci 1999, 40:1624-1629.
87. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444. 10.1038/nature07205, 18650914.
88. Courtois G, Gilmore TD. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene 2006, 25:6831-6843. 10.1038/sj.onc.1209939, 17072331.
89. Neri A, Chang CC, Lombardi L, Salina M, Corradini P, Maiolo AT, Chaganti RS, Dalla-Favera R. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell 1991, 67:1075-1087. 10.1016/0092-8674(91)90285-7, 1760839.
90. Fracchiolla NS, Lombardi L, Salina M, Migliazza A, Baldini L, Berti E, Cro L, Polli E, Maiolo AT, Neri A. Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies. Oncogene 1993, 8:2839-2845.
91. Rayet B, Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18:6938-6947. 10.1038/sj.onc.1203221, 10602468.
92. Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, Popplewell L, Offit K, Jhanwar SC, Chaganti RS. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998, 92:234-240.
93. Ohno H, Takimoto G, McKeithan TW. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 1990, 60:991-997. 10.1016/0092-8674(90)90347-H, 2180580.
94. Barth TF, Döhner H, Werner CA, Stilgenbauer S, Schlotter M, Pawlita M, Lichter P, Möller P, Bentz M. Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. Blood 1998, 91:4321-4330.
95. DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev 2012, 246:379-400. 10.1111/j.1600-065X.2012.01099.x, 22435567.
96. Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin P-C, Svensson MA, Kitabayashi N, Moss BJ, MacDonald TY, Cao X, Barrette T, Tewari AK, Chee MS, Chinnaiyan AM, Rickman DS, Demichelis F, Gerstein MB, Rubin MA. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res 2011, 21:56-67. 10.1101/gr.110684.110, 3012926, 21036922.
97. Jiao X, Wood LD, Lindman M, Jones S, Buckhaults P, Polyak K, Sukumar S, Carter H, Kim D, Karchin R, Sjöblom T. Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes Chromosomes Cancer 2012, 51:480-489. 10.1002/gcc.21935, 3302210, 22302350.
98. Greten FR, Eckmann L, Greten TF, Park JM, Li Z-W, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296. 10.1016/j.cell.2004.07.013, 15294155.
99. Karin M. NF- B as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009, 1:a000141-a000141. 10.1101/cshperspect.a000141, 2773649, 20066113.
100. Yang J, Splittgerber R, Yull FE, Kantrow S, Ayers GD, Karin M, Richmond A. Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest 2010, 120:2563-2574. 10.1172/JCI42358, 2898608, 20530876.
101. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 2010, 17:89-97. 10.1016/j.ccr.2009.12.008, 2818776, 20129250.
102. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR. " Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008, 205:1261-1268. 10.1084/jem.20080108, 2413024, 18490490.
103. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545. 10.1016/S0140-6736(00)04046-0, 11229684.
104. Chefetz I, Holmberg JC, Alvero AB, Visintin I, Mor G. Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFK{green}B pathway. Cell Cycle 2011, 10:2206-2214. 10.4161/cc.10.13.16348, 3154367, 21623171.
105. Alvero AB, Chen R, Fu H-H, Montagna M, Schwartz PE, Rutherford T, Silasi D-A, Steffensen KD, Waldstrom M, Visintin I, Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009, 8:158-166. 10.4161/cc.8.1.7533, 3041590, 19158483.
106. Böhlig L, Rother K. One function-multiple mechanisms: the manifold activities of p53 as a transcriptional repressor. J Biomed Biotechnol 2011, 2011:1-15.
107. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010, 21:11-19. 10.1016/j.cytogfr.2009.11.005, 2834864, 20018552.
108. Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 2012, 12:121-132.
109. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NF B. Genes Dev 2007, 21:1396-1408. 10.1101/gad.1553707, 1877751, 17510282.
110. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R, Haura EB. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005, 24:3397-3408. 10.1038/sj.onc.1208469, 15735721.
111. Lee H, Herrmann A, Deng J-H, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15:283-293. 10.1016/j.ccr.2009.02.015, 2777654, 19345327.
112. Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, Esterbauer H, Mueller M, Casanova E, Kenner L, Poli V, Eferl R. Stat3 Is a negative regulator of intestinal tumor progression in ApcMin mice. YGAST 2010, 138(e5):1003-1011.
113. Webster GA, Perkins ND. Transcriptional Cross Talk between NF-κB and p53. Mol Cell Biol 1999, 19(5):3485. 84141, 10207072.
114. Vaughan CA, Singh S, Windle B, Sankala HM, Graves PR, Andrew Yeudall W, Deb SP, Deb S. p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. Arch Biochem Biophys 2012, 518:79-88. 10.1016/j.abb.2011.12.006, 3272778, 22198284.
115. Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, Wieczorek M, Wagner T, Reichardt S, Werder Von A, Schmid RM, Weih F, Heinzel T, Saur D, Kramer OH. Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 2010, 29:2795-2806. 10.1038/onc.2010.46, 20190799.
116. Ichikawa H, Shimizu K, Hayashi Y, Ohki M. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 1994, 54:2865-2868.
117. Prasad DD, Ouchida M, Lee L, Rao VN, Reddy ES. TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. Oncogene 1994, 9:3717-3729.
118. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu X-F, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994, 6:146-151. 10.1038/ng0294-146, 8162068.
119. Tomlins SA. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648. 10.1126/science.1117679, 16254181.
120. Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, Li R, Ren C, Ayala G, Ittmann M. Activation of NF- B by TMPRSS2/ERG fusion isoforms through toll-like receptor-4. Cancer Res 2011, 71:1325-1333. 10.1158/0008-5472.CAN-10-2210, 3041849, 21169414.
121. Dryden NHN, Sperone AA, Martin-Almedina SS, Hannah RLR, Birdsey GMG, Khan STS, Layhadi JAJ, Mason JCJ, Haskard DOD, Göttgens BB, Randi AMA. The transcription factor Erg controls endothelial cell quiescence by repressing activity of nuclear factor (NF)-κB p65. J Biol Chem 2012, 287:12331-12342. 10.1074/jbc.M112.346791, 3320982, 22337883.
122. Juan Cai PKRSAKSSMLCSRC. Androgens induce functional CXCR4 through ERG factor expression in TMPRSS2-ERG fusion-positive prostate cancer cells. Translational Oncology 2010, 3:195. 2887649, 20563261.
123. Rylatt DB, Aitken A, Bilham T, Condon GD, Embi N, Cohen P. Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase. Eur J Biochem 1980, 107:529-537.
124. Kaidanovich-Beilin O, Woodgett JR. GSK-3: Functional Insights from Cell Biology and Animal Models. Front Mol Neurosci 2011, 4:40. 3217193, 22110425.
125. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406:86-90. 10.1038/35017574, 10894547.
126. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005, 65:2076-2081. 10.1158/0008-5472.CAN-04-3642, 15781615.
127. Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J, Fine HA. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 2008, 68:6643-6651. 10.1158/0008-5472.CAN-08-0850, 2585745, 18701488.
128. Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 2004, 23:7882-7892. 10.1038/sj.onc.1208068, 15361837.
129. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y, Minamoto T. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 2005, 334:1365-1373. 10.1016/j.bbrc.2005.07.041, 16043125.
130. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007, 110:735-742. 10.1182/blood-2006-12-060947, 1924475, 17463171.
131. Schulze-Osthoff K, Ferrari D, Riehemann K, Wesselborg S. Regulation of NF-κB activation by MAP kinase cascades. Immunobiology 1997, 198:35-49. 10.1016/S0171-2985(97)80025-3, 9442376.
132. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, Cong R, Franzoso G. Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature 2001, 414:308-313. 10.1038/35104560, 11713530.
133. Papa S, Zazzeroni F, Bubici C, Jayawardena S, Alvarez K, Matsuda S, Nguyen DU, Pham CG, Nelsbach AH, Melis T, De Smaele E, Tang W-J, D'Adamio L, Franzoso G. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol 2004, 6:146-153. 10.1038/ncb1093, 14743220.
134. Moscat J, Diaz-Meco MT, Rennert P. NF-kappaB activation by protein kinase C isoforms and B-cell function. EMBO Rep 2003, 4:31-36. 10.1038/sj.embor.embor704, 1315804, 12524517.
135. Lin X, O'Mahony A, Mu Y, Geleziunas R, Greene WC. Protein kinase C-theta participates in NF-kappa B activation induced by CD3-CD28 costimulation through selective activation of ikappa B kinase beta. Mol Cell Biol 2000, 20:2933-2940. 10.1128/MCB.20.8.2933-2940.2000, 85537, 10733597.
136. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP-Y, Baldwin AS. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes & Development 2008, 22:1490-1500. 10.1101/gad.1662308, 23923072.
137. Park YC, Lee CH, Kang HS, Chung HT, Kim HD. Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, enhances LPS-induced NO production from murine peritoneal macrophages. Biochem Biophys Res Commun 1997, 240:692-696. 10.1006/bbrc.1997.7722, 9398628.
138. Guha M. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. Journal of Biological Chemistry 2002, 277:32124-32132. 10.1074/jbc.M203298200, 12052830.
139. Zhao L, Lee JY, Hwang DH. The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-κB pathway. Biochem Pharmacol 2008, 75:1515-1525. 10.1016/j.bcp.2007.12.014, 18243161.
140. Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, Knaus UG. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol 2000, 1:533-540. 10.1038/82797, 11101877.
141. Trachootham D, Lu W, Ogasawara MA, Valle NR-D, Huang P. Redox regulation of cell survival. Antioxid Redox Signal 2008, 10:1343-1374. 10.1089/ars.2007.1957, 2932530, 18522489.
142. Bhakdi S, Martin E. Superoxide generation by human neutrophils induced by low doses of Escherichia coli hemolysin. Infect Immun 1991, 59:2955-2962. 258119, 1652556.
143. Morgan MJ, Liu Z-G. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res 2010, 21:103-115. 3193400, 21187859.
144. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
145. Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L, Tamassia N, Mantovani A, Cassatella MA, Locati M. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci USA 2009, 106:5282-5287. 10.1073/pnas.0810909106, 2664036, 19289835.
146. Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF- B signaling. Journal of Molecular Cell Biology 2011, 3:159-166. 10.1093/jmcb/mjr007, 3104013, 21502305.
147. Niu J, Shi Y, Tan G, Yang CH, Fan M, Pfeffer LM, Wu Z-H. DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J Biol Chem 2012, 287:21783-21795. 10.1074/jbc.M112.355495, 3381141, 22547075.
148. Zhang X, Liu S, Hu T, Liu S, He Y, Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 2009, 50:490-499. 10.1002/hep.23008, 19472311.
149. Taganov KD, Boldin MP, Chang K-J, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006, 103:12481-12486. 10.1073/pnas.0605298103, 1567904, 16885212.
150. Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Laco R, D'Onorio De Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G, Levrero M, Pediconi N. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol 2012, 56:855-861. 10.1016/j.jhep.2011.11.017, 22178270.
151. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706. 10.1016/j.cell.2009.10.014, 2783826, 19878981.
152. Li T, Morgan MJ, Choksi S, Zhang Y, Kim Y-S, Liu Z-G. MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat Immunol 2010, 11:799-805. 10.1038/ni.1918, 2926307, 20711193.
153. Zhang S, Shan C, Kong G, Du Y, Ye L, Zhang X. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK). Oncogene 2012, 31:3607-3620. 10.1038/onc.2011.523, 22105365.
154. Ahn D-W, Seo JK, Lee SH, Hwang J-H, Lee JK, Ryu JK, Kim Y-T, Yoon YB. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer. Pancreas 2012, 41:1048-1057. 10.1097/MPA.0b013e318249d62e, 22513291.
155. Walsby E, Pearce L, Burnett AK, Fegan C, Pepper C. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget 2012, 3:525-534. 3388182, 22619113.
156. Buontempo F, Chiarini F, Bressanin D, Tabellini G, Melchionda F, Pession A, Fini M, Neri LM, McCubrey JA, Martelli AM. Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. Cell Cycle 2012, 11:2467-2475. 10.4161/cc.20859, 22713244.
157. Salem K, Brown CO, Schibler J, Goel A. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. Exp Hematol 2013, 41:209-218. 10.1016/j.exphem.2012.10.002, 23063726.
158. Abaza MSI, Bahman AM, Al-Attiyah RJ, Kollamparambil AM. Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action. Tumour Biol 2012, 33:1951-1972. 10.1007/s13277-012-0456-6, 23011889.
159. Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cell Signal 2013, 25:106-112. 10.1016/j.cellsig.2012.09.008, 22975686.
160. Jiang X-J, Huang K-K, Yang M, Qiao L, Wang Q, Ye J-Y, Zhou H-S, Yi Z-S, Wu F-Q, Wang Z-X, Zhao Q-X, Meng F-Y. Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways. Cancer Letters 2012, 326:135-142. 10.1016/j.canlet.2012.07.030, 22863538.
161. Prasad S, Yadav VR, Sung B, Reuter S, Kannappan R, Deorukhkar A, Diagaradjane P, Wei C, Baladandayuthapani V, Krishnan S, Guha S, Aggarwal BB. Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. Clin Cancer Res 2012, 18:4942-4953. 10.1158/1078-0432.CCR-11-2805, 22832932.
162. Fabre C, Mimura N, Bobb K, Kong S-Y, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai Y-T, Richardson PG, Hideshima T, Anderson KC. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res 2012, 18:4669-4681. 10.1158/1078-0432.CCR-12-0779, 22806876.
163. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Letters 2008, 269:199-225. 10.1016/j.canlet.2008.03.009, 18479807.
164. Katsman A, Umezawa K, Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des 2009, 15:792-808. 10.2174/138161209787582156, 19275643.
165. Fuchs O. Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol 2010, 3:98-122.
166. Oiso S, Ikeda R, Nakamura K, Takeda Y, Akiyama S-I, Kariyazono H. Involvement of NF-κB activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells. Oncol Rep 2012, 28:27-32.
167. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008, 11:164-179. 10.1016/j.drup.2008.08.002, 18818117.
168. Kozakai N, Kikuchi E, Hasegawa M, Suzuki E, Ide H, Miyajima A, Horiguchi Y, Nakashima J, Umezawa K, Shigematsu N, Oya M. Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer. Br J Cancer 2012, 107:652-657. 10.1038/bjc.2012.321, 3419964, 22805327.